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Abstract
The parasitic protozoan Trypanosoma brucei causes Human African Trypanosomiasis and
Nagana in other mammals. These diseases present a major socio-economic burden to
large areas of sub-Saharan Africa. Current therapies involve complex and toxic regimens,
which can lead to fatal side-effects. In addition, there is emerging evidence for drug resis-
tance. AN5568 (SCYX-7158) is a novel benzoxaborole class compound that has been
selected as a lead compound for the treatment of HAT, and has demonstrated effective
clearance of both early and late stage trypanosomiasis in vivo. The compound is currently
awaiting phase III clinical trials and could lead to a novel oral therapeutic for the treatment of
HAT. However, the mode of action of AN5568 in T. brucei is unknown. This study aimed to
investigate the mode of action of AN5568 against T. brucei, using a combination of molecu-
lar and metabolomics-based approaches.Treatment of blood-stage trypanosomes with
AN5568 led to significant perturbations in parasite metabolism. In particular, elevated levels
of metabolites involved in the metabolism of S-adenosyl-L-methionine, an essential methyl
group donor, were found. Further comparative metabolomic analyses using an S-adenosyl-
L-methionine-dependent methyltransferase inhibitor, sinefungin, showed the presence of
several striking metabolic phenotypes common to both treatments. Furthermore, several
metabolic changes in AN5568 treated parasites resemble those invoked in cells treated with
a strong reducing agent, dithiothreitol, suggesting redox imbalances could be involved in the
killing mechanism.
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Author summary
Human African Trypanosomiasis (HAT) is a neglected tropical disease affecting mostly
rural communities of sub-Saharan Africa. New drugs for this parasitic disease have been
slow to develop, but one new class of drug, the benzoxaboroles, has proven to be highly
effective in preclinical models and holds promise for on-going clinical trials. The lead
compound in this class is AN5568, also known as SCYX-7158. Here, we study the effects
of AN5568 on intracellular metabolism of the parasite and show changes to pathways
involved in S-adenosyl-methionine metabolism. Further work shows similarities between
this drug and sinefungin, an inhibitor of methyltransferases and dithiothreitol, an endo-
plasmic reticulum stress inducer. These phenotypes provide new clues to the mechanism
of action of this compound.
Introduction
The monoflagellate protozoan parasite Trypanosoma brucei is the causative agent of Human Afri-
can trypanosomiasis (HAT), and is one of three species that cause Nagana in livestock [1]. HAT is
prevalent in sub-Saharan Africa and is responsible for a significant socio-economic burden. The
majority of HAT cases are caused by T. b. gambiense, in West Africa, with the remaining cases
attributed to T. b. rhodesiense, in the east [2]. Cases have decreased in recent years from 38,000 in
1998 to fewer than 3,000 in 2015 [3], leading to the gambiense form of the disease being targeted
by the WHO for elimination [4]. The disease is characterised by an early stage infection of the
mammalian bloodstream and other tissues, followed by a late stage where the parasite penetrates
the blood-brain barrier to proliferate within the central nervous system [1, 5].
Current therapeutics against HAT are inadequate, and in some cases, highly toxic, leading
to fatal side effects—including a reactive encephalopathy in significant numbers of patient
treated with melarsoprol [6]. There is evidence of resistance to these drugs in the field [7] and
current therapeutics frequently target only one T. brucei subspecies, or either early- or late-
stage HAT [8]. Thus, there is a desperate need for novel and improved therapeutics to combat
HAT.
An emerging class of boron-containing compounds known as benzoxaboroles have shown
promise as therapies against a wide range of diseases including, but not limited to those caused
by, viral [9], fungal [10], bacterial [11, 12] and parasitic [13] infections and inflammation [14].
These compounds have been reported to act as inhibitors of kinases [15], tRNA synthetases
[16, 17], CPSF3 [18, 19], phosphodiesterases [20, 21], and carbonic anhydrases [22].
The benzoxaborole AN5568 (SCYX-7158) was previously identified as a potent trypanocide
from a library screen of benzoxaborole 6-carboxamides [23]. In vivo analysis in murine models
showed brain exposure was high, with a maximum serum concentration (Cmax) of 10 μg/mL
and AUC0-24 hr higher than 100 μgh/mL, indicating favourable pharmacokinetics for a stage 2
HAT therapeutic [24]. Importantly, the compound can be administered orally and CNS con-
centrations are maintained above minimum inhibitory concentration (MIC) for at least 20
hours, sufficient for a twice daily dose [24]. The same study observed a 100% cure rate after a
regimen lasting 3 days or more, clearing both T. b. gambiense and T. b. rhodesiense infections
[24]. The compound started Phase II/III clinical trials in the last quarter of 2016. In summary,
AN5568 presents an exciting new therapeutic for the treatment of both early- and late-stage
HAT.
Whilst the pharmacokinetic parameters of the benzoxaborole are well understood, little
work has been carried out with regard to understanding the mode of action (MoA) of
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AN5568, aside from one recent study where proteins potentially binding the drug were identi-
fied through a chemoproteomics analysis and mutations in selected resistant lines were identi-
fied [25]. Indeed, few MoAs have been resolved to date for preclinical benzoxaboroles [16].
Firstly, the anti-fungal Tavaborole, which targets the leucyl-tRNA synthetase, and more
recently, an antimalarial that targets the cleavage and polyadenylation specificity factor subunit
3 (CPSF3) [19]. In addition, Crisaborole, a novel compound developed for the treatment of
mild to moderate atopic dermatitis, was shown to inhibit phosphodiesterase 4 (PDE4) [21].
An understanding of AN5568 MoA is crucial to enable the identification of the specific
drug target, development of further lead compounds, to assist in the choice of partner drugs in
combination therapies and to elucidate potential mechanisms of resistance.
Metabolomics, the study of all small molecules, or metabolites, in a given system, offers the
possibility of direct drug target identification when drugs inhibit specific enzymes [26, 27]. In
an ideal setting, drug inhibition of metabolic enzymes will result in elevated levels of the
enzyme’s substrate, with a corresponding reduction in the product [26–28]. In this study, we
utilised a liquid chromatography-mass spectrometry (LC-MS) platform, with the aim of eluci-
dating the MoA of AN5568, using the lab-adapted Lister 427 strain of T. b. brucei. Liquid-chro-
matography mass spectrometry analysis showed significant perturbations in methionine
metabolism in drug-treated cells. Further investigation showed that the benzoxaborole is sig-
nificantly antagonised in the presence of sinefungin, a non-specific methyltransferase inhibi-
tor. In addition, parasites treated with sinefungin and the endoplasmic reticulum stress
inducer dithiothreitol (DTT) both bear similar metabolic phenotypes to those observed follow-
ing treatment with AN5568.
Results
In vitro activity of AN5568
Efficacy of AN5568 was determined in both bloodstream form (BSF) and procyclic form
(PCF) parasites of the Lister 427 strain, by calculating the half maximal effective concentration
(EC50) (Table 1). In BSFs, mean EC50 was 193 ± 48 nM, whilst in contrast, the EC50 in PCF
parasites was almost 10-fold higher. This suggests some difference in benzoxaborole targeting
of the two developmental forms.
Further analyses on other trypanosomatids were carried out (Table 1). The EC50 in Trypa-
nosoma congolense, a closely-related trypanosome species of veterinary importance, was
509 ± 18 nM. In contrast, the promastigote stage of Leishmania mexicana, one of the trypano-
somatid species responsible for Leishmaniasis, exhibited an EC50 of 37.7 ± 3.6 μM, almost
200-fold and 25-fold higher than in T. b. brucei BSF and PCF respectively (Table 1).
AN5568 provokes profound changes in S-adenosyl-L-methionine levels in
T. b. brucei
Metabolomics analysis, using LC-MS, was carried out on T. b. brucei treated with AN5568 for
six hours at a concentration of 1.9 μM (10-fold EC50). This time point was chosen as metabolic
Table 1. EC50 concentrations calculated by alamar Blue for several trypanosomatids.
Organism EC50
T. b. brucei–BSF 193 ± 48 nM
T. b. brucei–PCF 1,500 ± 90 nM
T. congolense–BSF 509 ± 18 nM
L. mexicana—promastigote 37.7 ± 3.6 μM
https://doi.org/10.1371/journal.pntd.0006450.t001
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alterations occur much quicker than those of the genome or transcriptome. In addition, toxic
compounds can lead to widespread metabolic perturbation, which would mask the effects of
specific target inhibition as explained above. In this experiment, a total of 840 peaks were ten-
tatively identified and considered as metabolites (Fig 1). Of these, 50 were significantly altered
after drug treatment (Log2 fold-change =<-1,>1, P<0.05 [t-test]). These included a range of
metabolites involved in carbohydrate metabolism and lipid metabolism, but mostly amino
acid metabolism (S1 Table).
Fig 1. Metabolic changes associated with AN5568 treatment. A) A volcano plot showing the global metabolic changes associated with AN5568 treatment.
Numbers at red dots correspond to the following metabolites that were significantly increased 1) S-adenosyl-L-methionine (m/z: 398.1374, RT: 18.02 min,
7.67-fold), 2) 1,2-Dihydroxy-5-(methylthio)pent-1-en-3-one (m/z: 162.0350, RT: 17.24 min, 46.33-fold), 3) 5’-methylthioadenosine (m/z: 297.0896, RT: 7.75
min, 6.17-fold), 4) N6-acetyl-L-lysine (m/z: 188.1162, RT: 14.70 min, 2.83-fold), 5) adenine (m/z: 135.0546, RT: 7.71 min, 12.55-fold), 6) 4-hydroxy-
4-methylglutamate (m/z: 177.0637, RT: 15.3 min, 3.46-fold), 7) N6,N6,N6-trimethyl-L-lysine (m/z: 188.1524, RT: 23.54 min, 7.40-fold), 8) cyclic ADP-ribose
(m/z: 541.0608, RT: 16.90 min, 43.78-fold), 9) aminoacetone (m/z: 73.0528, RT: 7.67 min, 12.06-fold), 10) 8-amino-7-oxononanoate (m/z: 187.1208, RT: 13.75
min, 8.43-fold). Numbers at blue dots correspond to the following metabolites that were significantly decreased: 1) [PC(14:0)] 1-tetradecanoyl-sn-glycero-
3-phosphocholine (m/z: 467.3014, RT: 4.75 min, 0.35-fold), 2) sn-glycerol 3-phosphate (m/z: 172.0136, RT: 16.44 min, 0.40-fold), 3) D-glucosamine
6-phosphate (m/z: 259.0457, RT: 17.68 min, 0.47-fold), 4) 2-deoxy-D-ribose 5-phosphate (m/z: 214.0242, RT: 16.45 min, 0.39-fold), 5) Asp-Asp-Cys-Pro
(peptide) (m/z: 448.1256, RT: 17.64 min, 0.22-fold). These metabolites all have p-values of<0.05. B) Plots of individual metabolites perturbed after AN5568
treatment. There was an enrichment in metabolites involved in L-methionine metabolism. WT; wild type untreated, AN5568; wildtype treated for six hours at
10x EC50. C) A schematic to show the metabolites involved in methyltransferase reactions. Red ‘x’ indicates the typical S-adenosyl-L-methionine-dependent
methyltransferase reaction potentially affected by the benzoxaborole.
https://doi.org/10.1371/journal.pntd.0006450.g001
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Following treatment, we observed an enrichment in metabolites involved in methionine
metabolism (Fig 1), suggesting methyltransferases (MTase) as potential targets. The most sig-
nificant of these changes were in the levels of S-adenosyl-L-methionine (AdoMet) (m/z:
398.1374, retention time (RT): 18.01 min, 7.67-fold, P = 0.0096) and 5’-methylthioadenosine
(5’-MTA) (m/z: 297.0838, RT: 7.75 min, 6.17-fold, P = 4.61×10−6) (Fig 1). The levels of ade-
nine, a purine nucleobase that is also formed as a byproduct of AdoMet degradation, were also
increased (m/z: 135.0546, RT: 7.71 min, 12.55-fold, P = 0.0045) (Fig 1). The intermediate
decarboxylated AdoMet (dcAdoMet), a key aminopropyl donor used in polyamine biosynthe-
sis was not detected by LC-MS.
These metabolites are all associated with the degradation of methionine, in addition to the
recycling of this amino acid, which occurs in a cyclic metabolic pathway known as the Yang
cycle, methionine salvage, or the 5’-methylthioadenosine (MTA) cycle [29, 30]. This pathway
is crucial in maintaining a source of methyl groups for methyltransferase reactions as well as
other processes such as polyamine biosynthesis [31]. It is currently unknown whether the com-
plete Yang cycle is functional in T. brucei, although it is thought the parasite relies on uptake of
exogenous L-methionine, rather than recycling the amino acid [32]. Nevertheless, metabolo-
mics data were searched for further metabolites involved in the MTA cycle.
Interestingly, one peak was putatively identified as 1,2-dihydro-5-(methylthio)pent-1-en-3-one
(Fig 1A, red metabolite #2), which was significantly increased in AN5568-treated cells. This
metabolite plays a role in the regeneration of L-methionine through 2-oxo-4-methylthiobutanoate
(KMTB) [33]. The metabolomics data were further mined for 2-oxo-4-methylthiobutanoate, and
a mass consistent with this metabolite appeared to decrease post-treatment (S1 Table).
Whilst AdoMet was increased after AN5568 treatment, there was no corresponding
decrease in levels of S-adenosyl-L-homocysteine (AdoHcy), the by-product of methylation
reactions (Fig 1). Whilst there was no explanation for this observation, it is likely that homeo-
static processes are at play. Indeed, the activity of S-adenosyl-L-homocysteine hydrolase
(SAHH), the enzyme that catalyses the breakdown of AdoHcy into L-homocysteine and aden-
osine, is strictly regulated in other organisms [34]. L-homocysteine similarly remained
unchanged in the treated sample group. Importantly, two peaks corresponding to AN5568
were found, one for the parent ion and one for the boron-10 isotope (S1 Table).
Most other changes observed after AN5568-treatment were in metabolites involved in
amino acid metabolism (S1 Table), including increases in keto-arginine, modified lysines
(mono-, di- and tri-methyl-L-lysine and acetyl-L-lysine) and aminoacetone as well as
decreases in L-aspartate, L-proline, D-glucosamine 6-phosphate, L-carnitine and O-acetyl-L-
carnitine (S1 Table).
AN5568 provokes similar changes in procyclic T. b. brucei metabolism
PCF Lister 427 cells were exposed to 15 μM (10x EC50) AN5568 to investigate whether benzox-
aborole treatment induced similar changes in the metabolism of PCF cells to those observed in
BSF cells (Fig 2). Important to note was the higher concentration of AN5568 in PCF cultures
and a longer duration of drug exposure of 8 hours. The metabolic changes in PCF cells were
found to be similar to those in BSF cells, indicating that the molecular mechanisms of drug
action might also occur in the PCF stage.
Once again, the most significant changes involved L-methionine and AdoMet metabolism
(Fig 2). AdoMet (m/z: 398.1386, RT: 13.88 min) and 5’-MTA (m/z: 297.0898, RT: 7.69 min)
were both highly increased after drug treatment. In addition, mono-, di- and tri-methylated
lysines were again observed at high abundance. Finally, PCF cells also underwent changes in
glycoprotein metabolism, as indicated by increased levels of UDP-glucose (Fig 2).
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Comparative analysis of AN5568 activity to Sinefungin, a non-specific
methyltransferase inhibitor
To investigate the hypothesis that MTases are targeted by AN5568, we compared the metabo-
lomes of T. b. brucei cells treated with the non-specific AdoMet-dependent MTase inhibitor
sinefungin, to those of benzoxaborole-treated cells. Sinefungin is an AdoMet analogue con-
taining an aminomethylene group in place of the methylated sulfonium group that typically
acts as the methyl donor. It competes with AdoMet for MTase-binding and thereby inhibits
AdoMet-dependent MTases in a non-selective manner [35, 36].
Fig 2. Metabolic changes in PCF T. b. brucei after AN5568 treatment. Plots of individual metabolites perturbed after
AN5568 treatment. WT; wild-type untreated, AN5568; wildtype treated for eight hours at 15 μM (10x EC50).
https://doi.org/10.1371/journal.pntd.0006450.g002
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To determine whether AN5568 and sinefungin target similar pathways in vitro, isobolo-
gram experiments were conducted. Firstly, EC50 concentrations were calculated to be 193 nM
and 1 nM for AN5568 and sinefungin respectively. Subsequently, a fixed ratio isobologram, as
outlined previously by Fivelman and colleagues [37], was carried out to observe whether the
effect of using the two compounds simultaneously was greater (synergism) or less than (antag-
onism) the sum of the two compounds used separately. For each ratio (outlined in the meth-
ods), the fractional inhibitory concentration (FIC) was calculated by dividing the EC50 of one
drug in combination with the other, by the EC50 of that drug used alone. The sum of FIC was
calculated by adding the FIC for one drug to that of the other for each ratio. Synergism can be
defined as a mean FIC<0.5, whilst antagonism is likely occurring when FIC>1. Anything in
between suggests the compounds do not interact.
A scatter plot of FIC values showed higher FICs when the compounds were used in combi-
nation (Fig 3A). The mean total fractional inhibitory concentration (SFIC) for AN5568 and
sinefungin was calculated to be 1.21, suggesting slight antagonism between the two compounds.
Metabolomics experiments were subsequently carried out, and a principal component anal-
ysis (PCA) plot of three sample groups, wild-type, AN5568-treated and sinefungin-treated,
revealed an association between the two drug-treated sample groups, which separated from
the wild-type group (Fig 3B). Whilst the wild-type samples separated, both drug-treated
Fig 3. Comparative analyses of T. b. brucei treated with AN5568 and sinefungin, a non-specific methyltransferase
inhibitor. A) A fixed-ratio isobologram analysis was conducted using sinefungin and AN5568. B) Comparative
metabolomics analysis was carried out to assess any common metabolic alterations between sinefungin- and
AN5568-treated cells. A principal component analysis (PCA) plot of the 3 sample group was generated. C) Individual
metabolites were compared in terms of their fold change over a control group. D) AN5568 treatment leads to increased
abundance in components of the trypanothione biosynthesis pathway, whilst sinefungin treatment does not.
https://doi.org/10.1371/journal.pntd.0006450.g003
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samples overlapped, thereby suggesting similarities between the two sample groups. Indeed,
the main metabolic perturbations observed in AN5568-treated cells were also apparent in cells
treated with sinefungin (Fig 3C, S1 Table). Most notably, increases in AdoMet and 5’-MTA
were reproducible in both treatment groups. In addition, sinefungin-treated cells also exhib-
ited increased abundance of mono-, di- and tri-methylated lysines, as well as adenine, all of
which mirrored the metabolic changes in AN5568-treated cells.
Interestingly, AdoHcy remained unchanged after sinefungin treatment (Fig 3C), suggesting
that methyltransferase inhibition does not lead to decreased levels of AdoHcy that might be
expected from inhibition of this class of enzymes. This might be due to downstream metabolite
regulation of AdoHcy-hydrolase as previously mentioned [34].
There were also marked contrasts between AN5568- and sinefungin-treated cells. For
example, AN5568-treated cells clearly exhibited changes in the trypanothione biosynthesis
pathway, whilst these changes did not occur after sinefungin treatment (Fig 3D).
Distribution of carbon originating from L-methionine in the T. b. brucei
metabolome is not altered after AN5568 treatment
To investigate whether any alterations in methylation patterns could be observed across the
metabolic network, we carried out further LC-MS utilising Creek’s Minimal Medium (CMM)
[38]. Adding 100% [U-13C]-L-methionine to CMM allowed the observation of the dissemina-
tion of the isotope-labelled carbon atoms to be observed. As previously, cells were treated with
10× EC50 AN5568, and incubated for 6 hours under normal in vitro conditions.
A total of 25 peaks containing 13C isotopes were detected (17 in negative mode, 8 in positive
mode). Whilst the previously observed changes in methionine metabolism were reproducible, no
changes in carbon distribution were observed between AN5568-treated and untreated cells (Fig 4).
As expected, metabolic changes were consistent with previous experiments but intracellular
L-methionine was not 100% labelled, suggesting that uptake is relatively slow. Hasne and col-
leagues previously showed L-methionine uptake to be transporter mediated, and in BSF T. b.
brucei the transporter exhibits a Vmax of 28.8 ± 0.1 nmol/min/108 cells [32].
Interestingly, whilst only small amounts of AdoMet and 5’-MTA were detected in untreated
samples, they showed almost 100% labelling (Fig 4A), suggesting these metabolites all originate
from L-methionine. In contrast, these metabolites were only ~75% labelled in drug-treated
samples, suggesting they might be recycled, or the build-up initiates very quickly after drug
treatment. AdoHcy was also detected, with four 13C labels, as predicted. In addition, L-
cystathionine possessed four 13C labels, and was found to increase, as seen previously (Fig 4A).
Whilst arginine methylation was not observed in wild-type or drug-treated samples, meth-
ylated lysines that were seen to increase in previous experiments did show stable isotope labels
(S1 Fig), demonstrating that the carbon atoms in the methyl groups originated from L-methio-
nine. Lysine methylation has been shown to be involved in the degradation pathway of this
amino acid, which is ultimately converted to L-carnitine [39]. However, in neither sample
group was L-carnitine found to exhibit 13C labelling (S1 Fig), indicating a separate source of
this metabolite in T. b. brucei. Indeed, it was previously shown that the parasite has a high rate
of L-carnitine uptake from serum [40].
AN5568 treatment affects glycoprotein metabolism, but does not lead to
impaired VSG synthesis
Several metabolites putatively identified as components of glycoprotein metabolism were ele-
vated in benzoxaborole-treated cells. These included GDP-mannose, N-acetyl-D-glucosamine
and UDP-glucose (or UDP-galactose) (Fig 5A). These metabolites are important components
Metabolomic response to AN5568 treatment in T. brucei
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in the production of glycosylphosphatidylinositol (GPI) anchors that attach the variant surface
glycoproteins (VSG) to the trypanosome cell surface. To determine whether VSG biosynthesis
was affected by AN5568 treatment, Western blots were generated using the Lister 427 line,
which expresses VSG221 [41]. Firstly, lysates from cells treated with 10× EC50 AN5568 for 6
hours were probed with an αVSG221 antibody, and subsequently an α-enolase control (Fig
5B). No change in VSG221 expression was observed, although there appeared to be reduced
expression of the endogenous control. Indeed, further analysis of the metabolomics data
showed decreased levels of both the substrate and product (2-phospho-D-glycerate and phos-
phoenolpyruvate respectively) of this enzyme, for reasons we could not ascertain (S1 Table).
A further blot was generated using VSG cross-reacting determinant antibodies (VSG XR)
(Fig 5C) [42]. For this experiment, cell lysates were separated into membrane and soluble frac-
tions. Again, no changes were observed between the control and drug-treated samples, sug-
gesting VSG biosynthesis is not impaired on a protein level.
Comparing metabolic phenotypes of AN5568 treatment and ER stress
A major target for AdoMet donated methyl groups in T. b. brucei is the spliced leader cap
RNA structure that is spliced to all mature messenger RNAs in these cells. Recent publications
Fig 4. Tracing 13C distribution in AN5568-treated cells incubated with 13C-U-L-methionine. Cells were incubated with 200 μM [U-13C]-L-methionine for 6
hours. In addition, one sample group was incubated with 1.9 μM (10× EC50) AN5568. Metabolites involved in L-methionine metabolism detected in this
experiment were overlaid onto metabolic maps. In cases where 13C isotopes were detected, graphs incorporating the percentage labelling are shown. The
methionine salvage pathway (Yang cycle) is shown.
https://doi.org/10.1371/journal.pntd.0006450.g004
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have highlighted the presence of a unique ER stress response pathway in trypanosomatids [43–
45]. In response to unfolding proteins, and to ER stress inducers such as dithiothreitol (DTT),
a programmed cell death known as the spliced leader silencing (SLS) pathway is activated,
leading to programmed inhibition of spliced leader trans-splicing, as well as a reduction in
total RNA, increased cytoplasmic Ca2+ and DNA fragmentation [43]. Presumably, this would
also result in significant loss of RNA methylation. We therefore sought to compare the meta-
bolomic profiles of DTT and AN5568 treated cells in an LC-MS experiment, in order to deter-
mine whether the AdoMet signature was a specific response to the benzoxaborole treatment,
or a non-specific stress response (Fig 6).
No changes were observed in AdoMet (m/z: 398.1381, RT: 13.72 min, 2.53-fold, P = 0.230)
and adenine (m/z: 135.0545, RT: 9.48 min, 1.37-fold, P = 0.190), after DTT-treatment (Fig 6A).
Furthermore, 5’-MTA (m/z: 297.0889, RT: 6.70 min, 0.54-fold, P = 0.034) was decreased, com-
pared to wild-type control, not increased as observed in AN5568 treatment.
DTT treatment also led to metabolic changes in stress responses such as the trypanothione
biosynthesis pathway (Fig 6B). Modified lysines were increased, in a similar fashion to
AN5568 treatment. In particular, there was increased abundance of N6-acetyl-L-lysine (m/z:
188.1162, RT: 11.62 min, 4.26-fold, P = 0.0021), N6-methyl-L-lysine (m/z: 160.1211, RT: 18.99
min, 2.80-fold, P = 0.0004) and N6,N6,N6-trimethyl-L-lysine (m/z: 188.1528, RT: 18.09 min,
1.62-fold, P = 0.013) (Fig 6C), suggesting these changes are not unique to AN5568 treatment,
Fig 5. VSG biosynthesis in AN5568-treated cells. A) Three metabolites, all known to be involved in glycoprotein
biosynthesis, were found to be at higher levels in AN5568-treated cells. B) Western blots carried out on protein lysates
taken from AN5568-treated cells at a 6-hour time-point showed no significant changes in VSG expression at this time-
point. When the contrast of the resulting blot was increased, an extra band was seen in the 2× EC50-treated sample. C)
In addition to VSG expression, blots were probed with a VSG cross-reacting determinant (VSG XR) antibody. For this
experiment, protein lysates were fractionated to isolate the membrane fraction and separate it from the soluble
fraction. Most of the cellular GPI is found in the membrane, and no changes in expression could be seen in cells
treated with 10× EC50 for 6 hours. WT; untreated wild-type cells, AN5568; wild-type cells treated with AN5568 for 6
hours at 10× EC50.
https://doi.org/10.1371/journal.pntd.0006450.g005
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but potential indicators of metabolic responses to stress. Further similarities were also found
in keto-arginine (S2 Table).
In silico analysis of the T. brucei methyltransferome
Bioinformatics analysis of the entire kinase complement in the Tri-Tryps (T. brucei, T. cruzi
and Leishmania spp.) has greatly aided the identification of novel therapeutic targets, and
driven research into this class of enzymes [46]. Methyltransferases (MTases) are a different
class of highly specialised enzymes involved in the methylation of a large variety of substrates,
which carry equal potential as therapeutic targets. However, the T. brucei methyltransferase
complement has not been studied in great detail, with only ~25 experimentally characterised.
Indeed, only two large-scale MTase studies have previously been reported [47, 48]. Given the
metabolomics data generated, we sought to apply this in silico approach to characterise the T.
brucei “methyltransferome” (MTome), with the aim of identifying potential AN5568 targets.
Using a combination of interpro and pfam [49–51], a total of 143 genes containing MTase
domains were identified (Fig 7), the majority of which contained additional conserved
domains involved in substrate binding, transmembrane domains and localisation signalling
Fig 6. Comparing metabolic profiles of DTT and AN5568 treated cells. A heatmap was generated to highlight
similarities and differences in metabolism after treatment with the ER stress inducer dithiothreitol (DTT) and AN5568.
A) AdoMet metabolism was unaffected by DTT-treatment. B) Components of the oxidative stress response pathway were
altered after both treatments. In particular, DTT treatment led to a significant decrease in trypanothione disulphide. C)
Both DTT and AN5568 treatment result in increased levels of modified lysines and arginines, suggesting these are part of
a conserved trypanosomatid stress response. WT; wild-type untreated, AN5568; wild-type cells treated with AN5568 for 6
hours at 10× EC50, DTT; wild-type cells treated with DTT for 6 hours at 10× EC50.
https://doi.org/10.1371/journal.pntd.0006450.g006
Metabolomic response to AN5568 treatment in T. brucei
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006450 May 14, 2018 11 / 24
Fig 7. The T. brucei “methyltransferome”. A) A stylised tree depicting the entire methyltransferase complement of T. brucei, clustered based on domain class as
designated by Schubert and colleagues [52]. The arrangements of genes and branch lengths carry no significance as methyltransferases are highly diverse, making
generation of a phylogenetic tree challenging. Gene IDs in bold italics have been previously characterised. Abbreviations: TM: Tetrapyrrole methylase. B) Number of
members in each class of methyltransferase. Enzymes containing Rossmann-like folds and SET domains are numerous compared to the remaining classes. C)
Methyltransferases grouped by the substrate they methylate. The majority of MTases studied include spliced leader RNA MTases and protein arginine MTases. SET
domain-containing proteins are likely lysine MTases.
https://doi.org/10.1371/journal.pntd.0006450.g007
Metabolomic response to AN5568 treatment in T. brucei
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006450 May 14, 2018 12 / 24
domains (S3 Table). This list was categorised based on major folds present in the MTase
domains, similar to the methodology used in the Wlodarski and Petrossian & Clarke studies
[47, 48].
The majority of MTases (87/143) were found to exhibit Rossman-like folds. Most of the
experimentally characterised methyltransferases are present in this group, including arginine
methyltransferases, DOT methyltransferases and proteins involved in spliced leader methyla-
tion (Fig 7A). Furthermore, this group contains lipid MTases as well as rRNA and tRNA
MTases, most of which remain uncharacterised.
Another group with many representatives are proteins containing the conserved SET
domain (Fig 7A & 7B). These 33 genes are likely to be involved in protein lysine methylation,
in particular methylation of histones [53]. This group is far larger than expected (The S. cerevi-
siae genome encodes 12 SET domain MTases [47]), and could be indicative of the parasite’s
need to alter global gene expression throughout the varying life cycle stages. Further work is
required to confirm whether these proteins are true MTases. Indeed, none of the T. b. brucei
SET domain MTases have been experimentally characterised, yet proteins of this class have
been identified as therapeutic targets in cancer, and other protozoan parasites such as Plasmo-
dium [54], and could present an interesting group of trypanocidal candidate targets.
Like the S. cerevisiae MTome, the T. brucei genome also contains genes for other MTase
family members, including SPOUT domain MTases (8 genes), tetrapyrrole methylases (2
genes), a DNA/RNA-binding 3-helical bundle MTase (1 gene) a thymidylate synthase (1 gene)
a homocysteine MTases (1 gene), isoprenylcysteine carboxyl MTase (1 gene) and a TYW3
MTase (1 gene) (Fig 7). Finally, whilst not genuine methyltransferases, we chose to include the
8 predicted radical SAM enzyme family. These proteins typically cleave AdoMet to generate a
5’-deoxyadenosyl 5’-radical [55].
We attempted to overexpress several of the genes identified in the MTome screen based on
their essentiality in an RNAi screen [56] (Gene IDs: Tb927.10.3080, Tb927.10.7560, Tb927.10/
7850, Tb927.5.2050, Tb927.8.5040 and Tb927.6.2270). Whilst overexpression of some MTases
was achievable, their overexpression did not alter parasite sensitivity to AN5568, although in
the case of Tb927.8.5040 and Tb927.10.7850, resistance against sinefungin was noted (S2 Fig).
Microscopy analysis of AN5568 treated BSF cells
Morphological changes occurring during AN5568 treatment of T. b. brucei were investigated
using fluorescence microscopy. The nuclear and kinetoplastid DNA were stained using DAPI,
whilst Mitotracker was used to visualise the mitochondrion (Fig 8). Time-course experiments
were carried out on BSF T. b. brucei using a single dose of AN5568 at 2× EC50 (380 nM). Wild-
type controls were supplemented with an equal volume of DMSO.
No significant changes in morphology were observed 6 hours post-treatment (Fig 8A).
However, by 12 hours, most cells exhibited a rounded shape indicating adverse responses to
the compound (Fig 8A). In addition, DAPI staining revealed several nucleolar spots visible
after 12 and 24 hours, which could indicate a mitotic block. Interestingly, Mitotracker staining
showed that rather than a long, single, elongated mitochondrion typical of BSF T. brucei, the
organelle appeared patchy and swollen (Fig 8A). After 24 hours of 2× EC50 treatment, the
aforementioned phenotypes were far more pronounced and cells were rounded, with multiple
flagella and lack of flagellar extension. Furthermore, DAPI highlighted the presence of multiple
DNA-compartments.
To test whether AN5568 treatment affected T. b. brucei cell cycle and/or nuclear and kineto-
plast replication, NK analysis was conducted (Fig 8B). Percentages were calculated for cells
containing 1 of each organelle (1N1K); 1 nucleus and 2 kinetoplasts (1N2K); two of each
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Fig 8. Effect of AN5568 treatment on T. b. brucei cell division and morphology. T. b. brucei cells were incubated
with 2× EC50 concentration of AN5568 and cells were isolated for analysis by microscopy at specific time points. A)
After 6 hours of drug exposure, cells appeared normal under both direct light and DAPI, whilst mitochondria were
swollen. This phenotype was exaggerated by 12-hours post-treatment. After 24 hours, DAPI staining indicated a build-
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organelle (2N2K); 2 nuclei and 1 kinetoplast (2N1K), which suggests a defect in kinetoplast
replication; and finally, cells containing more than 2 of each organelle (MNMK).
The NK results mirrored the morphology analyses, and parasites exhibited no significant
changes in nuclear and kinetoplast number after 6 hours. However, by 12 hours, almost 20%
of cells contained 2 kinetoplasts and 2 nuclei, almost double the percentage of untreated para-
sites (Fig 8B).
Discussion
The benzoxaborole AN5568 (SCYX-7158) is a promising lead compound for treatment of
HAT, an infectious disease caused by T. brucei subspecies. Whilst the drug is currently await-
ing phase III clinical trials, the MoA is as-of-yet unknown. We sought to use a metabolomics-
based approach to reveal the metabolic perturbations induced by AN5568 in the lab-adapted
Lister 427 strain of T. b. brucei.
AN5568 treatment induced 50 significant metabolic perturbations in BSF trypanosomes,
with most identified as components of amino acid metabolism. In particular, there was an
enrichment of metabolites involved in L-methionine and AdoMet metabolism, leading us to
hypothesize that an MTase could be targeted. Indeed, AN5568 exhibits antagonism with sine-
fungin, a competitive AdoMet-dependent MTase inhibitor.
Further mass spectrometry analyses were undertaken to compare metabolic profiles of sine-
fungin, a known methyltransferase inhibitor and AN5568-treated parasites. These experiments
identified AdoMet and 5’-MTA as key players in methyltransferase inhibition.
Stable isotope-labelled [U-13C]-L-methionine was introduced to in vitro culture, in an
attempt to resolve the aforementioned metabolic changes. However, to our surprise, fewer
than 20 metabolites were found to incorporate carbon from L-methionine. This suggests that
a) L-methionine is not an essential source of carbon in terms of small molecule metabolism,
and b) carbon in methylation reactions is mainly transferred to larger molecules that could not
be detected by LC-MS, probably proteins. Furthermore, the absence of labelled methyl-argi-
nine in either untreated controls or drug-treated cells was surprising, and suggests that argi-
nine methylation is either a slower process than, for example, lysine methylation, or the
methyl groups used to methylate arginine do not originate from L-methionine or indeed
AdoMet. In addition, these processes could occur in different subcellular localisations or
compartments.
Interestingly, the metabolic profile of DTT treated cells bore some similarities to those
treated with AN5568, suggesting that T. b. brucei activates the conserved SLS pathway in
response to the benzoxaboroles, although DTT may also impair cellular redox balance and
induce other stresses in common with AN5568. These experiments were performed in order
to see whether the loss of trans-splicing associated with the SLS pathway might lead to accu-
mulation of AdoMet and related metabolites too, although it did not.
Several findings presented here are in agreement with a previous study of AN5568 MoA in
T. b. brucei [25]. Most notably, inhibition of cytokinesis was observed in both studies [25] (Fig
8). However, many drugs affect the ability of T. b. brucei to divide, and it is therefore not indic-
ative of a particular mode of action for this compound. Interestingly, in the context of these
data, Jones and colleagues found genomic deletions in one resistant cell line in a region
up of DNA-containing compartments in a significant number of cells, suggesting a cytokinetic defect. Scale bar
represents 5 μm. B) Cell cycle analysis was carried out by counting the numbers of nuclei and kinetoplasts in
AN5568-treated cells. Drug-treated cells were compared to a DMSO control at 6, 12 and 24 hour time-points, as
indicated by the horizontal lines.
https://doi.org/10.1371/journal.pntd.0006450.g008
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corresponding to the AdoMet decarboxylase (AdoMetDC) array. However, if AdoMetDC was
the benzoxaborole target, treatment would hypothetically lead to reduced levels of 5’-MTA
which was not seen (Fig 1).
Based on the data presented here, it seems that AN5568 has a significant effect on methio-
nine metabolism, and induces a stress response similar to the spliced leader silencing pathway.
However, we have not been able to assign these effects directly to a specific enzyme or particu-
lar methyltransferase reaction.
This study also presents, to our knowledge, the first collection of all predicted MTases in
the T. brucei genome. Using previous studies of H. sapiens [48] and S. cerevisiae [47] as a guide,
as well as publicly available pfam annotations from TriTrypDB [57], a dataset was generated
based on MTase class and fold. MTases are highly diverse and uniquely specific depending on
their biological function, and many are essential in protein synthesis, regulation of gene
expression, spliced leader methylation, and regulation of the cell cycle. They therefore present
a protein family of therapeutic interest.
One interesting finding in this regard is the large number of SET domain MTases which are
predicted lysine methylators, predicted in the T. brucei genome. It is likely that many of these
enzymes play crucial roles in histone modulation and maintenance of gene expression
throughout the extremely diverse life cycle stages of the parasite. The dataset requires further
refinement and expansion to include T. cruzi and Leishmania spp. Furthermore, the majority
of these proteins remain uncharacterised experimentally. We hope this dataset will inspire fur-
ther work on a group of proteins that in other settings, such as cancer biology, has recently
generated intense interest.
Although we now reveal metabolomics changes to trypanosomes treated with AN5568 we
cannot attribute a mode of action to the drug from this data, in common with the other high
throughput analysis on proteins that bind the drug and genetic differences in parasites selected
for resistance [18]. However, the results outlined here suggest that AN5568 action is not in a
catabolic or anabolic pathway, similar to other members of the benzoxaborole family [15, 16,
19, 21]. Further studies, for example, seeking genome scale over-expression libraries will be
required to definitively find the cellular target of the drug.
Methods
T. b. brucei in vitro culture
For BSF culture, the Lister 427 strain was used and maintained at 37˚C, 5% CO2. Cells were cul-
tured in HMI-9, supplemented with 10% foetal bovine serum (FBS). For [U-13C]-L-methionine
experiments, Creek’s Minimal Media was used [38], and isotope labelled metabolites were
added upon initiation of time-course experiments. Procyclic form culture also utilised Lister
427 (also identified as 29–13). PCFs were cultured in SDM-79 (Gibco, Cat#: 07490916N) [58],
supplemented with 10% FBS and 7.5 μg/mL hemin. PCF cell density was maintained between
5 × 105 cells/mL and 1 × 107 cells/mL and grown at 27˚C.
For overexpression of methyltransferases, BSF T. brucei Lister 427 were transfected with
methyltransferase open reading frames inserted into the pURAN vector. Transfection was car-
ried out as previously described [56]. Drug sensitivity in successfully transfected cell line was
tested by alamar blue.
Further parasite in vitro culture
T. congolense bloodstream form, strain IL3000, were cultured in TcBSF3 a recently developed
culture medium. Cultures were supplemented with 20% goat serum (Gibco) and 5% serum
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plus (Sigma). Density was maintained between 5 × 104 and 2 × 106 cells/mL and cultured were
incubated at 34˚C, 5% CO2.
Leishmania mexicana promastigotes were cultured in a modified Minimum Eagle’s
medium, termed HOMEM, supplemented with 10% FBS and 1% penicillin/streptomycin [59].
Cultures were maintained at 25˚C.
Alamar blue assays
To obtain in vitro EC50 values for specific compounds targeting T. b. brucei, the alamar blue
assay was applied in 96-well plates (adapted from [60]). Compounds were added starting with
the highest concentration (typically 100 μM) and serially diluted 1:2 over either 23 wells, leav-
ing one negative control. Subsequently, BSF T. b. brucei cells were added at a final density of
2 × 104 cells/mL. Plates were incubated at 37˚C, 5% CO2 and 20 μL of alamar blue reagent
(resazurin sodium salt, 0.49 mM in 1× PBS, pH 7.4) was added to each well after 48 hours.
Reduction of the alamar blue reagent was measured as a function of cell viability on a BMG
FLUOstar OPTIMA microplate reader (BMG Labtech GmbH, Germany) with λexcitation = 544
nm and λemission = 590 nm. The raw values were plotted against the log value of each concen-
tration of drug or compound, and EC50 values were calculated using a non-linear sigmoidal
dose-response curve. Each assay was performed in duplicate, and the final EC50 values pre-
sented represent a mean of three or four independent experiments.
For PCF parasites, plates were incubated for 72 hours prior to addition of alamar blue
reagent, and then incubated for another 48 hours. When BSF T. congolense were assayed, the
BSF T. b. brucei protocol was used, with an initial density of 2.5 × 105 cells/mL.
Isobologram assays
To investigate drug-drug interactions, isobologram analyses were carried out using a fixed-
ratio protocol previously described [37]. This assay uses the same principles as an alamar blue
assay to test for cell viability over a range of drug concentrations but testing two drugs
simultaneously.
For both drugs, the top concentrations used were chosen for the EC50 to fall near the mid-
point of a 12-part two-fold dilution series. We typically started with 16× EC50 and fixed ratio
solutions of drugs were made as follows: 10:0, 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, 1:9, 0:10. These
stocks were then added to the first column of 3 solid white flat-bottomed 96-well plates in
duplicate. The compounds were then serially diluted 1:1 with the final well of each row left
blank as a negative control. Finally, cells were added at a final concentration of 2 × 104 cells/
mL. Plates were then incubated for 48 hours and alamar blue reagent added as described
above. The plates were read after another 24 hour incubation on a BMG FLUOstar OPTIMA
microplate reader (BMG Labtech GmbH, Germany) as described above.
For each fixed ratio, an EC50 value was generated for either drug. These values were then
used to obtain fractional inhibitory concentration (FICs) indices, which are defined as the
EC50 values of drug in combination, divided by the EC50 values of those drugs acting alone
[61]. The isobologram was then generated by plotting the FICs of one drug against the other.
The overall mean SFIC was calculated for each combination by adding the values of each
individual FIC of either drug, and a mean SFIC value was used to assess whether the drug
interactions were synergistic, indifferent or antagonistic.
Metabolomics, LC-MS & data analysis
Samples for metabolomics analysis were acquired by rapidly quenching 8 × 107 cells in log
phase in a dry-ice/ethanol bath, to ~4˚C. For each sample group, four replicates were grown
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independently. In experiments involving stable isotope labelling, three replicates were used
and isotope-labelled compounds ([U-13C]-L-methionine, enrichment 99%, Cambridge Iso-
tope Laboratory Inc., cat: CLM-893-H-0.1) were added at the moment the time course was ini-
tiated. After quenching, samples were centrifuged for 10 minutes at 1,500 × g, 4˚C, and all
experimental steps hereafter were done on ice to keep the samples cold. Subsequently, 5 μL
supernatant was transferred to an Eppendorf containing 200 μL extraction solvent (Appendix
D), and the rest removed. Cells were re-suspended in the remaining supernatant and trans-
ferred to an Eppendorf so that they could be centrifuged at 1,500 × g for another 5 minutes.
Remaining supernatant was carefully removed, and the cells re-suspended in 200 μL extraction
solvent. All samples, including a blank and fresh medium control, were then left in a shaker at
4˚C for one hour. Subsequently, samples were spun down at 16,060 × g for 10 minutes, and the
supernatant was transferred to a 2 mL screw-top tube. From each sample, 10 μL was trans-
ferred to an empty tube to produce a quality control sample. Finally, air in the tubes was dis-
placed with argon gas to prevent oxidation of metabolites, and samples were stored at -80˚C
until they were analysed by liquid chromatography-mass spectrometry.
All mass spectrometry of metabolite samples was carried out by Glasgow Polyomics. Meta-
bolomics samples were separated by hydrophilic interaction liquid chromatography (HPLC)
using a ZIC-pHILIC (polymer-based HPLC) column (Merck). Two solvents were used in the
column. Solvent A was 20 mM ammonium carbonate in H2O and solvent B was 100% acetoni-
trile. Mass detection was carried out using an Exactive Orbitrap mass spectrometer (Thermo).
The mass spectrometer was run in positive and negative mode with an injection volume of
10 μL and a flow rate of 100 μL/minute.
Preparation of slides & microscopy
Mitochondria were stained using Mitotracker Red (Invitrogen) prior to fixation and mount-
ing. To achieve this, cells (typically 1 mL at 5 x 105 cells/mL) were incubated for 5 minutes at
37˚C, 5% CO2, with a final concentration of 100 nM Mitotracker. Upon completion, cells were
centrifuged for 5 minutes at 1,500 × g and washed twice in fresh medium before cells were
fixed.
Trypanosomes were grown to mid-log phase before control and treatment cultures were
started at a density of 2 × 105 cells/mL. For each time-point, at least 3 mL culture was centri-
fuged at 1,500 × g, washed twice with sterile 1× PBS, and finally re-suspended in 500 μL PBS.
Samples were fixed by adding a final concentration of 2% formaldehyde, and incubated for 15
minutes at room temperature. Subsequent to a wash with PBS, cells were transferred onto a
poly-L-lysine-coated slide, and left to air-dry in a safety cabinet. Dried slides were rehydrated
and washed in PBS, and a counterstain consisting of 1× PBS with 3 μM 4,6-diamidino-2-phe-
nylindole (DAPI) was applied to the slide, before mounting with a coverslip that was sealed
with clear nail varnish. Slides were analysed with a Zeiss axioscope (Scope.A1, Zeiss).
To ascertain whether compounds affected the T. b. brucei cell cycle, cells were prepared for
microscopy analysis as described above. Cells were then counterstained with DAPI and classified
according to the numbers of nuclei and kinetoplasts they had, as a direct correlation to phases of
the cell cycle, as described in several publications [62, 63]. Cells in G1 phase have one nucleus and
one kinetoplast (1N1K). Kinetoplast replication (S-phase) then initiates (1N2K) prior to nuclear
division (2N2K). Finally, completion of the cell cycle leads to two cells in G1 phase.
To analyse any potential changes in cell cycle,>300 cells were counted in multiple samples
and the number of cells in different cell cycle stages, as well as those in 2N1K and MNMK (‘M’
defined as ‘multiple’ organelles) phase, were calculated as percentages of the total number of
counted cells.
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To measure the distance between nucleus and kinetoplast, images were obtained from
DAPI-stained samples and these imported into the Fiji software [64]. Distances were measured
after the scale was set using the “measure” tool. For each sample group, 30 measurements were
taken from three independent microscopy experiments.
Computational methods
Graphical representation of data was created using the Graphpad Prism software (v6.0, GraphPad
Software, www.graphpad.com), R [65] or Inkscape. Statistical analyses were carried out using Gra-
phpad Prism, SPSS, Microsoft Excel and R. Further computational analysis was carried out using
R. Analysis of microscopy images, as well as processing of blots, was carried out using Fiji [64].
Raw data produced by the mass spectrometer were converted to the mzXML format using
msconvert [66]. This step also split the polarity of the data. Files were then converted to
peakML files with XCMS, which uses the Centwave function to pick peaks, converting every
individual file to the peakML output.
Metabolite identification was done using Ideom [67, 68]. Where targeted metabolomics
using stable isotopes labelling was carried out, mzMatch-ISO [69] was used for metabolite
identification, and all hits were then confirmed using Ideom. Putatively identified metabolites
were also analysed using the Metacyc [70] and Kegg [71] databases. Further metabolomics fig-
ures, including heat maps and PCA plots, were either created using Metaboanalyst [72],
Microsoft Excel, R or GraphPad Prism.
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S1 Table. Metabolomics dataset for AN5568 and sinefungin treatment of T. b. brucei Lister
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S1 Fig. Tracing 13C distribution in AN5568-treated cells: Lysine metabolism. Methylated
lysine contains methyl groups originating from L-methionine. Whilst lysine methylation has
been shown to be involved in the generation of L-carnitine, no 13C-labeled L-carnitine was
detected in wild-type or AN5568-treated cells.
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S2 Fig. AN5568 and sinefungin sensitivity in methyltransferase overexpression lines. Six T.
brucei overexpression lines were generated and their sensitivity to both AN5568 and sinefun-
gin was tested. Whilst no methyltransferase conferred resistance to AN5568 when overex-
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